

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In Re Application of:**

**Steven W. Sutton and**

**Timothy W. Lovenberg**

**Application No.: 10/537,732**

**Filing Date: June 7, 2005**

**For: METHOD FOR IDENTIFYING MODULATORS OF HUMAN OREXIN-2  
RECEPTOR**

**Confirmation No.: 6621**

**Group Art Unit: 1645**

**Examiner: Not Yet Assigned**

DATE OF DEPOSIT: May 8, 2007

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☒ Copies of reference numbers 23 - 27 listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers        on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(ii).

☐ Copies of references        -        are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number        , filed        for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- ☐ The relevance of those listed references which are not in the English language is as follows:

**DOCKET NO.: JJPR-0177 / ORT1509-PCT - 3 -**

**PATENT**

There are no listed references which are not in the English language.

The attached references identified on the 1449 form were cited in the European Search Report dated April 4, 2007 that was received in the corresponding European application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Date: May 8, 2007

/Phillip A. Singer/  
Phillip A. Singer  
Registration No. 40,176

WOODCOCK WASHBURN LLP  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. JJPR-0177 / ORT1509-PCT		Application No. 10/537,732	
				Applicant Steven W. Sutton and Timothy W. Lovenberg			
				Filing Date June 7, 2005		Group 1645	
				Confirmation No. 6621			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
	23	WO 01/85693	11/15/01	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	24	Gartlon, J.E. et al., "Role of OX <sub>1</sub> and OX <sub>2</sub> receptors in the motor activity response to the orexins," <i>Society for Neuroscience Abstracts</i> , <b>2001</b> , 27(1), 848					
	25	Jaszberenyi, M. et al., "Effects of orexins on the hypothalamic-pituitary-adrenal system," <i>Journal of Neuroendocrinology</i> , <b>2000</b> , 12(12), 1174-1178					
	26	Mignot, E. et al., "Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders," <i>Nature Neuroscience, Nature America, Inc.</i> , <b>2002</b> , 5 Suppl., 1071-1075					
	27	Sakurai, T. et al., "Oxerins and oxerin receptors: A family of hypothalamic neuropeptides and G Protein-coupled receptors that regulate feeding behaviour," <i>Cell</i> , <b>1998</b> , 92, 573-585					
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			